Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for A2R345

Entry ID Method Resolution Chain Position Source
AF-A2R345-F1 Predicted AlphaFoldDB

No variants for A2R345

Variant ID(s) Position Change Description Diseaes Association Provenance
No variants for A2R345

No associated diseases with A2R345

6 regional properties for A2R345

Type Name Position InterPro Accession
domain Ribonuclease III domain 915 - 1077 IPR000999-1
domain Ribonuclease III domain 1094 - 1301 IPR000999-2
domain Helicase, C-terminal 370 - 535 IPR001650
domain Dicer dimerisation domain 565 - 659 IPR005034
domain DEAD/DEAH box helicase domain 22 - 154 IPR011545
domain Helicase superfamily 1/2, ATP-binding domain 15 - 214 IPR014001

Functions

Description
EC Number
Subcellular Localization
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

No GO annotations of cellular component

Name Definition
No GO annotations for cellular component

5 GO annotations of molecular function

Name Definition
ATP binding Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.
helicase activity Catalysis of the reaction: ATP + H2O = ADP + phosphate, to drive the unwinding of a DNA or RNA helix.
metal ion binding Binding to a metal ion.
ribonuclease III activity Catalysis of the endonucleolytic cleavage of RNA with 5'-phosphomonoesters and 3'-OH termini; makes two staggered cuts in both strands of dsRNA, leaving a 3' overhang of 2 nt.
RNA binding Binding to an RNA molecule or a portion thereof.

4 GO annotations of biological process

Name Definition
defense response to virus Reactions triggered in response to the presence of a virus that act to protect the cell or organism.
gene silencing by RNA A process in which an RNA molecule reduces expression of target genes. This can occur pre-transcriptionally by assembly of heterochromatin and prevention of transcription or co- or post-transcriptionally by targeting RNAs for degradation or by interfering with splicing or translation. This process starts once the inhibitory RNA molecule has been transcribed, and includes processing of the RNA such as cleavage, modifications, transport from the nucleus to the cytoplasm, loading onto the RISC complex, and the effect on transcription or translation.
regulation of defense response to virus Any process that modulates the frequency, rate or extent of the antiviral response of a cell or organism.
RNA processing Any process involved in the conversion of one or more primary RNA transcripts into one or more mature RNA molecules.

No homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
No homologous proteins
10 20 30 40 50 60
MTVAATVLPA GEDAPAYRPR SYQVEMFEAS LKENIIVTMG TGSGKTHIAL LRIIKELESN
70 80 90 100 110 120
PHKLIWFLTP TVALCLQQFK FLSDNIPAVR ARTLTSLDKV ELWTEQPVWD AILKEMQVVV
130 140 150 160 170 180
STHAVLADAM SHGFVKITQL GLMIFDEAHH CMRRHPANKI MQDFYHPALE RHGAEAVPKI
190 200 210 220 230 240
LGLTASPVVR SNRQELLKIE SNLDAVCKTP RTHRSELMTH THRPHLQQIL FTPVLLDDLQ
250 260 270 280 290 300
VGSKTLKALV SAWTSLRLED DPYIKKLRKS PLDGRALQKV LESGKTYCND QLKRFATRSL
310 320 330 340 350 360
HIFEELGEWA ADYFIHASIE QLKARAGNSA DTMGWTDEEK AYLLDIVSKL PIPNIDLTHS
370 380 390 400 410 420
DPDRIPISSK FRSLLEFLDT KGEPNFSGLI FAKQRATVSV MEKLLSIHPV TKHRFRCASF
430 440 450 460 470 480
VGWSGGGSKD VLGELLDARM QRDTLSEFRT GQKNLIIATD VLEEGIDISA CSVVVCFDKP
490 500 510 520 530 540
PNLKSFVQRR GRARHRQSTY AIMFATDDES SALSKWEDLE QAMIEAYEDD ERRLREAWAL
550 560 570 580 590 600
EAINEEVVER LEVQSTGAVL TADTAVAHLN HFCAVLPRQP YASNEPEFSY EKDDADLLRG
610 620 630 640 650 660
TVTLPSCVHP GVRRIQGQRW WQTERAARKE AAFQAYKRLY EFGLLSDHLL PFKRNLELKE
670 680 690 700 710 720
TDLTNLPALV EVSEQYDPWV DWACSWSSPD VHQTRIAIKH NGDSRMCIRL TSPTSLPPVE
730 740 750 760 770 780
PMTLFWDSET IYTLDFDKPK RMKEIAAESI ENMRLATALY LQAASSRQMR PEQDFVTLFG
790 800 810 820 830 840
PDLTDLELAE WLNKHAGDEP ALEVYSRKDF PTVMGIVRDR SRYNEPMLFK RWVVSGQDDT
850 860 870 880 890 900
PIVELECDAV PKRRNLLHRQ TLAAKQPDSE TPAISSKIRL ILAENCTIDK LPYAETIFGR
910 920 930 940 950 960
FISVILDRLE ATLVATRLCE TILRDLEFSS IRHIITAITA PSAQSLTNYQ RYEFFGDSVL
970 980 990 1000 1010 1020
KFTVSCQLFF QHPNWHEGYL SEGRDEIVQN SRLARAALDA GLDAFIMNKM FTPRKWSAPL
1030 1040 1050 1060 1070 1080
ISEKISLTPK QRTMSTKVLA DVVEALIGAS YIDGGFAAAH ACIHRFLPEV NLENIDRTTA
1090 1100 1110 1120 1130 1140
PMPKDGVTNH TLNDDHLMAH IGYTFTNKSL LVESLTHPSC QFDTTTQSYQ RLEFLGDAVL
1150 1160 1170 1180 1190 1200
DMAIMSTLLS HPREIPQGLM TKIKHAVVNA NLLAFFCMEF ALTEKRTNVQ VTPTGTVTLN
1210 1220 1230 1240 1250 1260
PSTEHIELWR FMRYQGAHLQ TARDLALSRH SSLRGSIIHG LKHSPSYPWK SLSQLNADKF
1270 1280 1290 1300 1310 1320
FSDIIESILG AIFIDSHGNL AECEKFLERL GLLRYLRRIL KDEVDVMHPR NIAQQMAKGE
1330 1340 1350 1360 1370 1380
IRFEVLRVPN EGGGGGEDDG ATYRCTVKMA GVDGVAVVVE GCLTSEEAEI TAAERAVEIL
VGRGCSL